The DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index.
Cardiovascular complications and risk of death in sickle-cell disease
Abstract
In sickle-cell disease, a point mutation in the β-globin chain causes haemoglobin to polymerise within erythrocytes during deoxygenation, altering red blood cell rheology and causing haemolysis. Improvements in health infrastructure, preventive care, and clinical treatments have reduced the morbidity and mortality of sickle-cell disease in developed countries. However, as these patients live longer, the chronic effects of sustained haemolytic anaemia and episodic vaso-occlusive events drive the development of end-organ complications. Cardiopulmonary organ dysfunction and chronic kidney injury have a large effect on morbidity and premature mortality, and typically accelerate in the second decade of life. These processes culminate in the development of pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, and sudden death. In this Series paper, we review the mechanisms, clinical features, and epidemiology of major cardiovascular complications in patients with sickle-cell disease and discuss how screening and intervention could reduce their incidence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Self-citationDefinitions and Diagnosis of Pulmonary Hypertension
Hoeper, M. M., Bogaard, H. J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., Langleben, D., Manes, A., Satoh, T., Torres, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.032 · Cited by 1,766
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Self-citationRiociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H.-A., D'Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,401
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationPathogenesis and Treatment of Sickle Cell Disease
Bunn, H. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371107 · Cited by 1,154
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Self-citationThe molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease
Fang, X., Ardehali, H., Min, J., & Wang, F. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00735-4 · Cited by 1,081
Ware, R. E., de Montalembert, M., Tshilolo, L., & Abboud, M. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30193-9 · Cited by 977
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Self-citationA Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Vichinsky, E., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A., Hassab, H., Achebe, M. M., Alkindi, S., Brown, R. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 624
Metadata
- Authors
- Gladwin, M. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Gladwin, Mark T
- ORCID
- Gladwin, Mark T
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 387
- Issue
- 10037
- Pages
- 2565-2574
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2439745533
- Cited by
- 164
- References
- 100
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 21 · 2023: 9 · 2022: 13 · 2021: 17 · 2020: 17 · 2019: 18 · 2018: 17 · 2017: 13 · 2016: 5
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL103455, T32HL007563, R01HL125886, R01HL098032, T32HL110849)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- sickle cell disease, cardiovascular complications, mortality, pulmonary hypertension, left ventricular diastolic dysfunction, sudden death, cardiac arrhythmias, chronic kidney injury, target organ damage, hemolytic anemia, vascular occlusion, screening, premature mortality
- MeSH terms
- Anemia, Sickle Cell, Heart Diseases, Hemolysis, Humans, Hypertension, Pulmonary, Risk Factors, Death, Sudden, Cardiac, Early Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular complications and risk of death in sickle-cell disease. https://app.cochat.ai/papers/10.1016/s0140-6736(16)00647-4
- The paper
- Gladwin, M. T. (2016). Cardiovascular complications and risk of death in sickle-cell disease. The Lancet. https://doi.org/10.1016/s0140-6736(16)00647-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.